CN1981840A - 一种抗炎止血中药组合物及其制备方法 - Google Patents
一种抗炎止血中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN1981840A CN1981840A CN 200510129943 CN200510129943A CN1981840A CN 1981840 A CN1981840 A CN 1981840A CN 200510129943 CN200510129943 CN 200510129943 CN 200510129943 A CN200510129943 A CN 200510129943A CN 1981840 A CN1981840 A CN 1981840A
- Authority
- CN
- China
- Prior art keywords
- group
- lotus
- solution
- methanol
- hemostasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 230000023597 hemostasis Effects 0.000 title description 112
- 239000003814 drug Substances 0.000 claims abstract description 129
- 208000032843 Hemorrhage Diseases 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 230000008569 process Effects 0.000 claims abstract description 3
- 208000004145 Endometritis Diseases 0.000 claims abstract 2
- 208000006374 Uterine Cervicitis Diseases 0.000 claims abstract 2
- 206010046914 Vaginal infection Diseases 0.000 claims abstract 2
- 206010008323 cervicitis Diseases 0.000 claims abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 60
- 238000012360 testing method Methods 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 239000007788 liquid Substances 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 claims description 17
- 241001438943 Callicarpa kwangtungensis Species 0.000 claims description 17
- YFVGIJBUXMQFOF-SAXLCNSLSA-N Linarin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 YFVGIJBUXMQFOF-SAXLCNSLSA-N 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 15
- 239000013558 reference substance Substances 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000012567 medical material Substances 0.000 claims description 8
- 230000002439 hemostatic effect Effects 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 5
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 claims description 4
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000004809 thin layer chromatography Methods 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 238000011003 system suitability test Methods 0.000 claims description 3
- FZRCKLPSHGTOAU-UHFFFAOYSA-N 6-amino-1,4-dimethylcyclohexa-2,4-diene-1-carbaldehyde Chemical compound CC1=CC(N)C(C)(C=O)C=C1 FZRCKLPSHGTOAU-UHFFFAOYSA-N 0.000 claims description 2
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000003760 hair shine Effects 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 148
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract description 147
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract description 147
- 206010027514 Metrorrhagia Diseases 0.000 abstract description 2
- 235000017595 Callicarpa japonica Nutrition 0.000 abstract 1
- 240000003690 Callicarpa japonica Species 0.000 abstract 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 abstract 1
- 201000008100 Vaginitis Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 100
- 241001465754 Metazoa Species 0.000 description 65
- 241000699670 Mus sp. Species 0.000 description 59
- 239000008187 granular material Substances 0.000 description 43
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 42
- 239000000243 solution Substances 0.000 description 32
- 206010053567 Coagulopathies Diseases 0.000 description 29
- 230000035602 clotting Effects 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 239000000284 extract Substances 0.000 description 25
- 230000000740 bleeding effect Effects 0.000 description 23
- 230000037396 body weight Effects 0.000 description 21
- 241000700159 Rattus Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 108010094028 Prothrombin Proteins 0.000 description 14
- 102100027378 Prothrombin Human genes 0.000 description 14
- 229940039716 prothrombin Drugs 0.000 description 14
- 229920000669 heparin Polymers 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 238000010998 test method Methods 0.000 description 12
- 238000012449 Kunming mouse Methods 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 10
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 9
- 230000023555 blood coagulation Effects 0.000 description 9
- 208000031169 hemorrhagic disease Diseases 0.000 description 9
- 229960002897 heparin Drugs 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- 230000004856 capillary permeability Effects 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000000701 coagulant Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 4
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 3
- 108090000056 Complement factor B Proteins 0.000 description 3
- 102000003712 Complement factor B Human genes 0.000 description 3
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 3
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 3
- 229960001008 heparin sodium Drugs 0.000 description 3
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 3
- 229960003147 reserpine Drugs 0.000 description 3
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229960000620 ranitidine Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- AKXOIHNFHOEPHN-CQSZACIVSA-N (6ar)-1-methoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-2-ol Chemical compound C([C@H]1N(C)CC2)C3=CC=CC=C3C3=C1C2=CC(O)=C3OC AKXOIHNFHOEPHN-CQSZACIVSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 240000001579 Cirsium arvense Species 0.000 description 1
- 241000729173 Cirsium japonicum Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101000651443 Rattus norvegicus Prothrombin Proteins 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000009642 citrate test Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- -1 flavone compound Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- NIFIFKQPDTWWGU-UHFFFAOYSA-N pyrite Chemical class [Fe+2].[S-][S-] NIFIFKQPDTWWGU-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000009705 sanhuang Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 生药量/体重(g/kg) | 动物数 | 出血时间(S)Mean±Std. |
空白阳性水低水中水高醇低醇中醇高 | -648164816 | 1114121314161615 | 539.18±177.29386.21±134.37*377.17±154.28*283.69±86.88*203.21±68.00*▲▲3 10.25±206.08*294.06±191.35*254.00±126.34*▲ |
组别 | 生药量/体重(g/kg) | 动物数 | 凝血时间(S)Mean±Std. |
空白阳性水低水中水高醇低醇中醇高 | -648164816 | 1114131414161615 | 41.36±17.9023.00±7.97*21.08±3.12*21.50±6.17*15.64±0.84*▲▲18.44±4.12*18.94±4.51*17.00±3.23*▲ |
组别 | 生药量/体重(g/kg) | 动物数 | 复钙均值(S)Mean±Std. |
空白阳性水低水中水高醇低醇中醇高 | -3.61.83.67.21.83.67.2 | 119111110101110 | 93.91±21.4059.50±9.01*55.18±20.90*44.78±4.96*▲45.60±9.78*▲47.30±11.34*31.86±8.49*▲▲32.95±7.87*▲▲ |
误差来源ABCD(误差) | SS13607.5165250.512200.362879.03 | F2222 | S6803.7582625.236100.181439.51 | F值4.757.44.2 | P>0.05<0.05>0.05 |
组别 | 动物数 | 剂量(/Kg) | 出血时间(秒) |
生理盐水组断血流颗粒组蓟荷高剂量组蓟荷中剂量组蓟荷低剂量组 | 1515151514 | -6.0g颗粒8.0g生药4.0g生药2.0g生药 | 444.93±202.35324.33±195.96235.66±162.27▲264.33±136.77▲▲542.07±225.84 |
组别 | 动物数 | 剂量(/Kg) | 凝血时间(秒) |
生理盐水组断血流颗粒组蓟荷高剂量组蓟荷中剂量组蓟荷低剂量组 | 1616161512 | -6.0g颗粒8.0g生药4.0g生药2.0g生药 | 100.75±36.2571.81±24.14▲▲67.75±20.52▲▲69.06±32.21▲▲74.91±26.25▲ |
组别 | 动物数 | 剂量(/Kg) | 凝血时间(秒) |
生理盐水组断血流颗粒组蓟荷高剂量组蓟荷中剂量组蓟荷低剂量组 | 1918141616 | -6.0g颗粒8.0g生药4.0g生药2.0g生药 | 166.34±55.84154.33±29.11171.67±52.45131.59±50.28▲170.96±39.19 |
组别 | 动物数 | 剂量(/Kg) | 复钙时间(秒) |
生理盐水组断血流颗粒组蓟荷高剂量组蓟荷中剂量组蓟荷低剂量组 | 119101110 | -3.6g颗粒6.0g生药3.0g生药1.0g生药 | 93.91±21.4059.50±9.01▲32.95±7.87▲31.86±8.49▲47.30±11.34▲ |
组别 | 动物数 | 剂量(/Kg) | 出血时间(秒) |
生理盐水组模型组断血流颗粒组蓟荷高剂量组蓟荷中剂量组蓟荷低剂量组 | 151411101113 | -67.5U6.0g颗粒8.0g生药4.0g生药2.0g生药 | 354.67±230.26693.57±406.82△600.00±308.14462.20±231.27▲221.81±118.35▲▲▲343.07±153.75▲▲▲ |
组别 | 动物数 | 剂量(/Kg) | 凝血时间(秒) |
生理盐水组模型组断血流颗粒组蓟荷高剂量组蓟荷中剂量组蓟荷低剂量组 | 10118889 | --6.0g颗粒8.0g生药4.0g生药2.0g生药 | 142.30±69.34261.09±54.69△△△173.87±43.99▲▲146.93±67.04▲▲▲166.00±61.14▲▲▲134.27±34.47▲▲▲ |
组别 | 动物数 | 剂量(/Kg) | 溃疡个数(个) |
生理盐水组模型组雷尼替丁组蓟荷高剂量组蓟荷中剂量组蓟荷低剂量组 | 121212121112 | -60mg8.0g生药4.0g生药2.0g生药 | 0.00±0.0013.33±7.61△△△2.41±2.027.66±3.62▲6.63±3.50▲9.00±8.99 |
组别 | 动物数 | 剂量(/Kg) | 出血个数 | 未出血个数 |
生理盐水组模型组雷尼替丁组蓟荷高剂量组蓟荷中剂量组蓟荷低剂量组 | 121212121112 | -60mg8.0g生药4.0g生药2.0g生药 | 011△△△2▲▲6▲810 | 121△△△10▲▲6▲32 |
组别 | 动物数 | 剂量(/Kg) | 凝血酶原时间(秒) | 部分凝血酶原时间(秒) |
生理盐水组断血流颗粒组蓟荷高剂量组蓟荷中剂量组蓟荷低剂量组 | 1212121212 | -3.6g颗粒6.0g生药3.0g生药1.5g生药 | 15.90±2.0116.82±4.4715.27±0.6816.5±1.7915.25±2.19 | 14.35±2.5819.31±14.0516.99±3.7520.35±7.5421.08±2.84 |
组别 | 动物数 | 剂量(/Kg) | 血小板(109/L) |
生理盐水组断血流颗粒组蓟荷高剂量组蓟荷中剂量组蓟荷低剂量组 | 1515141515 | -6.0g颗粒8.0g生药4.0g生药2.0g生药 | 886.25±69.83881.62±65.70892.87±76.91864.12±105.98875.00±81.84 |
组别 | 动物数 | 剂量(/Kg) | 肿胀度(克) |
生理盐水组醋酸泼尼松片蓟荷高剂量组蓟荷中剂量组蓟荷低剂量组 | 1314151414 | -0.012g8.0g生药4.0g生药2.0g生药 | 0.0036±0.00210.0010±0.0018△△△0.0009±0.0012△△△0.0011±0.0015△△△0.0012±0.0014△△△ |
组别 | 动物数 | 剂量(/Kg) | 光密度值 |
生理盐水组醋酸泼尼松片蓟荷高剂量组蓟荷中剂量组蓟荷低剂量组 | 1010101010 | -0.012g8.0g生药4.0g生药2.0g生药 | 0.028±.0070.016±0.004△△△0.003±0.006△△0.017±0.003△△△0.020±0.005△△△ |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510129943A CN1981840B (zh) | 2005-12-13 | 2005-12-13 | 一种抗炎止血中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510129943A CN1981840B (zh) | 2005-12-13 | 2005-12-13 | 一种抗炎止血中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1981840A true CN1981840A (zh) | 2007-06-20 |
CN1981840B CN1981840B (zh) | 2010-05-05 |
Family
ID=38164871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200510129943A Active CN1981840B (zh) | 2005-12-13 | 2005-12-13 | 一种抗炎止血中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1981840B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102370901A (zh) * | 2010-08-25 | 2012-03-14 | 天津天士力制药股份有限公司 | 一种治疗肾病的药物组合物及其制备方法 |
CN112359485A (zh) * | 2020-11-18 | 2021-02-12 | 同高纺织化纤(深圳)有限公司 | 无纺布及其制备方法以及具有该无纺布的卫生材料 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1689615A (zh) * | 2004-04-21 | 2005-11-02 | 范崔生 | 一种止血中药组合物及其制备方法 |
CN100348256C (zh) * | 2005-04-22 | 2007-11-14 | 李小安 | 一种妇科止血药 |
-
2005
- 2005-12-13 CN CN200510129943A patent/CN1981840B/zh active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102370901A (zh) * | 2010-08-25 | 2012-03-14 | 天津天士力制药股份有限公司 | 一种治疗肾病的药物组合物及其制备方法 |
CN112359485A (zh) * | 2020-11-18 | 2021-02-12 | 同高纺织化纤(深圳)有限公司 | 无纺布及其制备方法以及具有该无纺布的卫生材料 |
Also Published As
Publication number | Publication date |
---|---|
CN1981840B (zh) | 2010-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101856449B (zh) | 一种清热利湿,活血通淋中药组合物及制备方法和质量检测方法 | |
CN1768854B (zh) | 一种用于溃疡性结肠炎的中药胶囊制剂 | |
CN102755386B (zh) | 一种抗病毒的药物组合物,含其制剂及其应用 | |
CN102274401B (zh) | 一种治疗胃病的中药制剂及其制备方法和检测方法 | |
CN103028065B (zh) | 一种紫香益母制剂及其制备方法和检测方法 | |
CN103169864B (zh) | 增液汤配方颗粒及其制备方法、用途和检测方法 | |
CN105911192A (zh) | 一种半枫荷活血化瘀活性部位的提取方法及指纹图谱检测方法 | |
CN100443498C (zh) | 白薇总皂苷及其皂苷化合物在抗炎药物中的应用 | |
CN100496555C (zh) | 解毒止痒中药组合物及其制备方法 | |
CN1981840B (zh) | 一种抗炎止血中药组合物及其制备方法 | |
CN1883566B (zh) | 一种消炎药物及其制备方法 | |
CN101406542B (zh) | 一种用于止嗽定喘祛痰的中药口服制剂 | |
CN102526427A (zh) | 治疗胃肠疾病的中药组合物及质量检测方法 | |
CN1923263B (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN1803179B (zh) | 一种中药组合物及其制备方法和有效成分的检测方法 | |
CN101057895B (zh) | 治疗妇科疾病的妇炎舒制剂及其质量检测方法 | |
CN105434840A (zh) | 一种川参通制剂的制作方法 | |
CN102284021B (zh) | 一种小儿宣肺止咳颗粒组合物及其制备方法和质量检测方法 | |
CN107412462B (zh) | 一种黄龙咳喘胶囊的制备方法 | |
CN102342986B (zh) | 固公果根中治疗腹泻的有效部位及制备方法 | |
CN101433608A (zh) | 固公果根中治疗腹泻的有效部位及制备方法 | |
CN101019915A (zh) | 一种三七止血胶囊及其制备方法和质量控制方法 | |
CN100542595C (zh) | 一种中药组合物及其制备方法和分析方法 | |
CN103134896A (zh) | 一种治疗慢性前列腺炎的中药制剂的检测方法 | |
CN102614248B (zh) | 一种治疗中风与胸痹的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGXI HONGXING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FAN CUISHENG Effective date: 20091225 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20091225 Address after: Jiangxi Fu County in Dongxiang province Fuzhou City Industrial Park Jiangxi Hongxing Pharmaceutical Co. Ltd. post encoding: 330006 Applicant after: Jiangxi Hongxing Pharmaceutical Co., Ltd. Address before: 05 mailbox postal code: 2 unit 05, north courtyard, Jiangxi Medical College, 603 Bayi Avenue, Nanchang, Jiangxi, China: 330006 Applicant before: Fan young Sheng Co-applicant before: Sun Jiyin Co-applicant before: Lv Wuqing |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |